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Cardiac arrhythmias during dobutamine infusion
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(42-322)
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(48-312)
49
(7-249)
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256
(55-508)
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205
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251
(57-549)
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(47-588)
96
(7-820)
241
(59-446)
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99
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DOB
15 mg/
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208
(44-446)
198
(47-503)
123
(21-634)
212
(45-438)
261
(74-493)
135
(21-847)
p 0.01 0.001 0.112 0.018 0.015 0.127
Table 1. Some characteristics of HF patients
Age (mean) 61.7011.75
Gender (m/f) 30 / 17
BMI 28.07
HT 21 (%44.7)
HLP 35 (%74.5)
DM 29 (%61.7)
LVEF (all HF group's average) %30.4010.4
SVEF (LVD group) %26.667.19
PEF-KY (n) 8 (%17)
DEF-KY (n) 39 (%83)
HF: Heart failure, BMI: body mass index, HT: hypertension, HLP: hyperlipidemia, DM: diabetes
mellitus LVEF: left ventricle ejection fraction LVD: left ventricle dysfunction, PEF: preserved
ejection fraction LEF: low ejection fraction
Table 2. miRNA expression fold changes
According to the normal
at admission
According to the normal
at discharge
miR- 22 - 2.39 f - 1.23 f
miR- 24 - 2.07 f - 1.59 f
miR- 92b + 2.33 f + 3.0 f
miRNA (miR): microribonucleic acid
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Introductıon: The new generation continuous-ﬂow left ventricle assist devices
(LVAD) is an option for heart transplantation for end-stage heart failure. These kind of
devices which developped with new technology, are implanted widely all over the
world for bridge to transplantation as well as destination therapy. The effect of LVAD
therapy on pulmonary artery pressure (PAP) in patients with ﬁxed pulmonary artery
hypertension (PAH) who are not good candidate for heart transplant, is an important
research topic. In this study, we evaluated the course of PAP in LVAD therapy and its
effect to post-transplant results.
Materıals-Methods: Between December 2008 and June 2013, continuous-ﬂow-
LVAD implantation were performed in 73 patients. Mean age was 48.39 years and
87% was male. The common etiology for heart failure was Idiopathic dilated
cardiomyopathy (69%). 9 of 73 patients (12,3%) were succesfully bridged to trans-
plantation. 8 patients with ﬁxed PAH were included in this study. PAP levels were
retrospectively compared before LVAD, after LVAD and after heart transplantion.
Results: Mean PAP before LVAD,after LVAD therapy and after heart transplant was
respectively 59,6 mmHg,34.8mmHg and 32.8mmHg. The reduction of PAP was
evident in patients supported with LVAD more than 60 days and consequently
complications related to PAH were lower in this group. Two patients were died in
early period of after heart transplant, the common feature of them was short support
time after LVAD. Mean support time was 34 days. PAP was still high after LVAD and
the main cause of mortality was right heart failure related multi-organ failure.
Conclusıon: The study is limited due to low-number of patients. But the decline of
ﬁxed PAH even it is refractory to vasodilator therapy was found in our analysis. As
a conclusion we think that LVAD therapy before heart transplantation, in patients
with decompansated heart failure and severe PAH, improves the results of heart
transplantation.
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Aim: The relationship of miRNA levels in patients admitted to the hospital because of
acute decompensated heart failure (ADHF) as cause of heart failure, in hospital and
short-term cardiovascular events, hospital readmission and mortality.
Method: Our study included 47 patients with decompansated HF (10 non-ischemic
and 37 ishemic origin) and 30 healty subjects (mean age: 57.138.32, %46.6 men).
Peripheral blood was withdrawn and kept under appropriate circumstances to evaluate
miR-22, miR-24 and miR-92b levels. When sample collection was completed, the
levels of mRNA detected from peripheral blood cells (leukocytes) were calculated
using the method PCR. The fold differences between groups were calculated as
average and miRNA6Ct(the amount of normalized miRNA in a cycle) values were
used for comparison.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTResults: %63.8 of the patients were male and mean age was 61.7011.75. 39 patient
had left ventricular systolic dysfunction and the average LVEF was %26.667.19. All
patients', in-hospital mortality was %6.3, 1-month mortality rate was %4.5 and in this
duration hospital readmission rate was %31.8. There was a signiﬁcant fold change (>2
fold) between the patients miR-22, miR-24 and miR-92b levels and the control group.
However, the signiﬁcant changes in miRNA, both in low and preserved left ventricular
systolic function or in terms of etiology of HF showed no difference. Similarly, there
was no correlation between the6Ct values in terms of in-hospital and short-term
cardiovascular endpoints.
Conclusıon: Although there was a signiﬁcant fold change in miRNA levels in
patients hospitalized for ADHF, it did not correlate with the clinical endpoints ana-
lysed with6Ct values.PP-066
The Relationship between Heart Failure Stage/Symptom Class and Anxiety
Etem Çelik1, Serkan Çay1, Sani Murat2, Fatih Öksüz1, Tayyar Cankurt1,
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Background: Anxiety disorders are most common encountered psychiatric disorders.
There is no data regarding the relationship between this widely seen situation and
heart failure stage/symptom class.
Aim: The aim of this study is to evaluate the relationship between various stages of
anxiety disorders and heart failure stages/symptom classes.
Methods: A total of consecutive 419 patients with a mean age of 57.914.4 years
(age range, 18-96 years) admitted with the symptoms of heart failure and/or with risk
factors for heart failure were included in the study. Beck's anxiety inventory including
21 evaluation sentences was applied to all study participants to measure the level and
severity of anxiety symptoms of persons. Measured total scores were used to grade the
severity as minimal, mild, moderate, and severe.
Results: Two hundred and nineteen patients (52.3%) were male, 247 (58.9%) had
hypertension, 139 (33.2%) had diabetes, and 248 cases (59.2%) had coronary heart
disease. Stage A heart failure was present in 113 patients (27.0%), stage B in 119
patients (28.4%), stage C in 116 patients (27.7%), and stage D in remaining 71 cases
(16.9%). With regard to NYHA classiﬁcation, 228 patients (54.4%) had class I
symptoms, 101 (24.1%) had class II symptoms, 31 (7.4%) had class III symptoms, and
class IV symptoms were found in remaining 59 patients (14.1%). The mean left
ventricular ejection fraction of all population was 54.2%  12.4 and the mean Beck's
anxiety score was 13.49.0. Neither heart failure stages nor symptom classes were
found to be statistically different among 4 study groups regarding anxiety scores and
severity (all p>0.05) (table).
Conclusıon: There was no association between heart failure stage/class and anxiety
score/severity in a wide population of heart failure patients.ERS C107
Table 1
Heart
failure
stage Stage A Stage B Stage C Stage D
P value
for
trend
Anxiety
score
14.3  8.7 12.8  8.5 12.5  9.2 14.5  9.7 NS
NYHA class NYHA I NYHA II NYHA III NYHA IV
Anxiety
score
13.5  8.6 12.8  9.0 11.7  9.3 15.1  9.9 NS
NS, not signiﬁcant
The baseline clinical characteristics of the patients and control group
Patient group (n¼66) Control group (n¼31) p value
Age (years)
(meanSD)
62.2714.84 60.706.85 0.113
Hypertension
(n, %)
36 (54.5%) 19 (61.3%) 0.685
Smoking (n, %) 6 (9.1%) 4 (12.9%) 0.722
Obesity (n,%) 14 (21.2%) 12 (38.7%) 0.117
LVEF (%) 29.5(18-45) 65 (54-73) <0.001
Glucose (mg/dl) 91.6616.41 93.2213.69 0.647
Creatinine
(mg/dl)
0.9 (0.6-1.2) 0.7 (0.6-1.1) <0.001
Hemoglobin
(g/dl)
12.881.96 14.160.97 <0.001
CRP (mg/L) 0.7 (0.3-19.7) 0.33 (0.3-0.68) <0.001
Pro-BNP (mg/ml) 3442.5 (21.78-20806) 85.53 (18.16-184.10) <0.001
Fetuin-A (mg/ml) 72.94 (14.11-648.88) 526.36 (282.98-726.58) <0.001
CRP: C-reactive protein, BNP: B-type natriuretic peptide, CRP: C-reactive protein, LVEF: left
ventricular ejection fraction
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Association of CA-125 Levels with Presence of Permanent Atrial Fibrillation in
Patients with Systolic Heart Failure
Hakki Kaya1, Hasan Yucel1, Ali Zorlu2, Hakan Gunes2, Mehmet Birhan Yimaz2
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Background: Atrial Fibrillation (AF), a dysrhythmia with negative consequences on
mortality and morbidity, is noted in approximately 30% of patients with Heart Failure
(HF). Permanent AF is a situation in which the sinus rhythm can't be restored with the
usual therapy. Paroxysmal and persistent atrial ﬁbrillations eventually yield in
permanent AF, particularly in patients with HF. An association of CA-125 with poor
prognosis in patients with HF has been demonstrated previously by a number of
studies. The purpose of the present study was to investigate the relationship between
CA- 125 levels and permanent AF in patients with systolic HF.
Methods: The study included 216 patients (152 males and 64 females) with stable
systolic HF (EF 45%). The patients were classiﬁed into two groups: those with
permanent AF (n¼76) and those without permanent AF (all in sinus rhythm on index
ECG, hence called patients in sinus rhythm) (n¼140). Patients were followed up for
HF related hospitalization and mortality for 21 months.
Results: Patients with permanent AF had higher levels of CA-125 compared to those
with sinus rhythm (113.1 U/ml vs. 34.5 U/ml; p<0.001). Patients with permanent AF
had larger left atrial diameter compared to those with sinus rhythm (4.60.6 vs
4.40.7 cm, p¼0.025). There were more patients with moderate-severe mitral
regurgitation (50.0 vs. 26.6%; p¼0,001), moderate-severe tricuspid regurgitation
(53.9 vs. 25.7%; p<0.001) in the group with permanent AF compared to those with
sinus rhythm. Number of HF related hospitalizations was also signiﬁcantly higher
among the patients with permanent AF than in those with sinus rhythm on follow up
(63.2 vs. 47.9%; p¼0.031). CA-125 levels predicted presence of permanent AF in
patients with stable HF (AUC: 0.742, 95% CI 0.673-0.812, p<0.001). Furthermore,
CA-125 level of more than 150 U/ml predicted presence of permanent AF with
a sensitivity of 37% and speciﬁcity of 91% in a group of patients with systolic HF, and
associated with 5.699 times more likelihood of permanent AF (Odds ratio, 95% CI
2.727-11.907, p<0.001).
Conclusıon: CA-125 levels were signiﬁcantly higher among the stable systolic HF
patients with permanent AF compared to those with sinus rhythm and there was
a higher rate of hospitalizations in patients with permanent AF due to HF on follow
up. It seems a high CA-125 level (>150 U/ml) can rule-in (high speciﬁcity) the
presence of permanent AF in patients with HF.
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Background: Activation of the immune system has been implicated in the patho-
genesis of heart failure. Fetuin-A (a2-Heremans Schmid glycoprotein), as a negative
acute-phase reactant, prevents the increase of inﬂammatory response of the body
against it by increasing the cellular uptake of cationic inhibitors of proinﬂamatory
cytokine synthesis. Fetuin-A levels in the blood were shown to be inversely associated
with the proinﬂammatory cytokines such as IL-1 beta, IL-6 and TNF-alpha levels. In
our study, it was aimed to evaluate the importance of serum fetuin-A levels in the
diagnosis and assessment of left ventricular systolic heart failure and to compare with
the level of serum CRP and pro-BNP.
Methods: We enrolled 66 patients with a diagnosis of heart failure and 31 patients
without a diagnosis of heart failure forming a control group who admitted to the
Department of Cardiology at Uludag University Medical Faculty, Bursa, between July
2011 to January 2012. After informed consent for biochemical examinations had been
obtained, blood samples were collected from the controls and the patients with chronic
heart failure. Both study and control group patients had detailed echocardiographic
examination.
Results: Median serum fetuin-A levels of the heart failure group were signiﬁcantly
lower than the control group (p<0,001) [respectively 72.94 (14.11 to 648.88) mg/ml,C108 JACC Vo526.36 (282.98 to 726.58) mg/ml]. Serum CRP and pro-BNP levels in the heart failure
group were detected signiﬁcantly higher than the control group (p<0.001). In all
cases, fetuin-A levels positively correlated with left ventricular ejection fraction (EF)
and negatively correlated with pro-BNP and CRP (respectively, r:0.732 p<0.001,
r:-0.542 p<0.001, r:-0.352 p<0.001). ROC analysis was done for the serum fetuin-A,
the area under the ROC curve was 96% and the ‘cut off’ level was determined as
270,45 ug / ml for fetuin-A giving a sensitivity of 86,36% and speciﬁcity of 96,77%
for the diagnosis of the left ventricular heart failure (p<0,001).
Conclusıons: In conclusion, our study is the ﬁrst study as evidence for decreased
serum fetuin-A levels in patients with left ventricular systolic heart failure. Serum
fetuin-A was a diagnostic marker with high sensitivity and speciﬁcity for the patients
with systolic heart failure and showed that it was as powerful marker as serum pro-
BNP. However, due to a multifunctional protein, serum fetuin-A is affected by many
factors. Prospective studies with larger sample sizes are needed to better clarify the
diagnostic and prognostic role of fetuin-A in patients with heart failure.PP-069
A Comparison of the Effects of Carvedilol and Nebivolol on Oxidative Stress
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Background: Heart failure (HF) has a poor prognosis despite advances in its
management. Clinical and experimental studies have provided substantial evidence
that oxidative stress is enhanced in HF. The third-generation beta-blockers, carve-
diolol and nebivolol have other beneﬁcial features such as vasodilator and antioxidant
effects in addition to beta1 receptor blocking effect. Thus, they may be considered as
ﬁrst line therapy in HF patients. However, it is unclear that carvedilol may be superior
to nebivolol in HF patients. Thus, we investigated the effects of carvedilol and
nebivolol on oxidative stress parameters in non-ischemic HF patients.
Methods: We included 56 asymptomatic non-ischemic HF patients with ejection
fraction (EF) 40%. The patients were randomized to carvedilol (n¼29, 18 male)
or nebivolol (n¼27, 18 male) groups. We evaluated clinical and laboratory
characteristics which are associated with oxidative stress such as total oxidative
status (TOS), total antioxidant capacity (TAC), oxidative stress index (OSI), uric
acit, gamma glutamyl transferase (GGT), alkaline phosphatase (ALP). Echocardiog-
raphy was performed. The left atrial size, left ventricular (LV) diameter and volumes,
wall thickness were measured. LV EF was calculated by Simpson's method.
Isovolumetric relaxation time (IVRT), isovolumetric contraction time (IVKT),
ejection time (ET) were measured. Also, myocardial performance index (MPI) were
calculated.
Results: Basaline clinic and demographic characteristics were similarly in carvediolol
and nebivolol groups. LV EF (29.64.8 vs 315, p¼0.20), MPI (0.700.13 vs
0.670.11, p¼0.23), diameters and volumes was similar between two groups. TAC
[1.25 (0.39-2.71) vs 1.23 (0.65-1.88) mmol Trolox Eq/l, p¼0.92], TOS [2.64 (0.62-
9.20) vs 2.45 (1.06-4.40) mmol H2O2 Eq/l, p¼0.88], OSI [253 (45-1020) vs 213 (76-
538) AU, p¼0.44], üric acit (9.30.6 vs 9.30.6 mg/dl, p¼0.32), ALP (7737 vs
6820 U/L, p¼0.60), GGT [31 (11-106) vs 33 (8-88) U/L, p¼0.58] were also
comparable in both groups.
Conclusıon: Our ﬁndings show that carvedilol and nebivolol appear similar to their
effects on oxidative stress parameters in non-ischemic HF patients.
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